UK Issues Safety Alert on Weight-Loss Drugs and Birth Control Interaction
In a major update affecting women’s health worldwide, including in Pakistan, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a safety warning. The alert highlights that popular weight-loss medications like Ozempic, Wegovy, Mounjaro, and Saxenda may reduce the effectiveness of oral contraceptives.
What Prompted the Warning?
The MHRA reviewed 40 reported cases of unintended pregnancies among women taking these GLP-1 receptor agonist medications, which are often prescribed for weight management and diabetes.
“Mounjaro, in particular, may reduce the effectiveness of oral contraceptives,” said the MHRA.
- 26 of these cases were linked to Mounjaro
- Other reports involved semaglutide-based drugs (Ozempic, Wegovy) and Saxenda (liraglutide)
Warning for Women Planning Pregnancy
The MHRA strongly advises against using these drugs during pregnancy or while trying to conceive, due to limited safety data. Women are urged to:
- Continue using contraception for two months after stopping GLP-1 medications
- Avoid these drugs entirely if planning pregnancy
This warning holds special relevance for Pakistan, where off-label weight-loss drug use is increasing and often goes unregulated.
Why Oral Contraceptives May Not Be Enough
These medications commonly cause gastrointestinal side effects, such as vomiting and delayed digestion, which may interfere with oral contraceptive absorption. As a result, the MHRA recommends:
“Women should use barrier methods like condoms alongside oral contraceptives.”
Experts Caution on Fertility Effects of Weight-Loss Meds
Dr. Channa Jayasena, a leading reproductive endocrinologist, noted:
“GLP-1 drugs may enhance fertility in women with obesity—raising the risk of unintended pregnancy if birth control fails.”
This dual effect—improved fertility and weakened contraception—is particularly concerning in countries like Pakistan, where reproductive education and access to healthcare are still developing.
Read more on: Regular Coffee Tied to Healthy Aging in Women
Misuse of Weight-Loss Drugs Raises Risks
Dr. Alison Cave, MHRA’s Chief Safety Officer, issued a clear message:
“These drugs are not for cosmetic weight loss. They should be used only under medical supervision.”
In Pakistan, social media trends often promote off-label use of Ozempic and similar drugs, making this warning especially timely.
To find the right solutions for you; book a consultation with our experts now!
Recommendations for Pakistan’s Healthcare Community
For healthcare professionals in Pakistan, this warning presents an opportunity to strengthen clinical protocols and public education. Key action points include:
✅ Screen women of reproductive age before prescribing weight-loss drugs
✅ Advise dual contraceptive use while on GLP-1 medications
✅ Educate patients on delaying conception for at least two months post-treatment
✅ Discourage misuse of weight-loss medications through public awareness campaigns
Final Thoughts: A Wake-Up Call for Safe Medication Use
The MHRA’s safety warning on weight-loss drugs and birth control should serve as a crucial reference for Pakistan’s healthcare providers and patients. As the demand for weight-loss solutions rises, prioritizing safe medication practices and contraceptive planning is essential to protect women’s health.
